Financial Data and Key Metrics Changes - Astrana Health reported total revenue of 478.7million,a3745.2 million, a 13% decrease from 52millionintheprioryearperiod[24]−Year−to−dateadjustedEBITDAincreasedby15117.6 million in the first three quarters of 2023 to 135.3millioninthefirstthreequartersof2024[12][25]−NetincomeattributabletoAstranaforthequarterwas16.1 million, down 27% from 22.1millionintheprioryearquarter[25]−Earningsperdilutedshareforthequarterstoodat0.33, down from 0.47intheprioryearperiod[26]−Thecompanyendedthequarterwith348 million in cash and cash equivalents and total debt of 442million[26]BusinessLineDataandKeyMetricsChanges−Membershipwasaround1millionmembersasofSeptember30,withover200primarycareprovidersandover900specialistsaddedtothenetwork[13]−Fullriskbusinessaccountedforapproximately61200 million in additional top line from CHS in Q4, with a negative 4millionadjustedEBITDAimpact[31][20]CompanyStrategyandDevelopmentDirection−Thecompanyfocusesonfourstrategicpillars:sustainablygrowingmembership,increasingalignmentwithoutcomes,achievingsuperiorpatientoutcomes,anddrivingoperatingleverage[8][10]−TheintegrationofCollaborativeHealthSystemsisunderway,withexpectationsforsignificantrevenuecontributionsinthefuture[20][21]−Thecompanyaimstohavearoundtwo−thirdsofitscapitationrevenuecomingfromafullriskecosystembyJanuary1,2025[14]Management′sCommentsonOperatingEnvironmentandFutureOutlook−ManagementexpressedoptimismaboutincreasedMedicaidfundinginCalifornia,whichisexpectedtobenefitcommunitiesserved[33][34]−ThecompanyanticipatesstabilizationinMedicaidtrendsasredeterminationprocessesnormalize[44][49]−Managementhighlightedtheimportanceoflocalmarketdynamicsandtheneedfortailoredapproachestocaredelivery[38][39]OtherImportantInformation−Thecompanyisfocusedontheseamlessintegrationofacquisitionsandstrengtheningitsfinancialposition[28]−Adjustedguidanceforfull−yearrevenueisnowbetween1.95 billion and 2.03billion,withadjustedEBITDAexpectedtorangebetween165 million and 175 million [27] Q&A Session Summary Question: Impact of CHS on guidance - The addition of CHS is expected to contribute approximately 200 million in top line for Q4, with a negative $4 million EBITDA impact [31] Question: Proposition 35 in California - Management is pleased with increased Medicaid funding, which is expected to enhance network sustainability and quality [33][34] Question: Medical cost trends and reinvestment areas - Medical cost trends are stabilizing, with reinvestments focused on clinical and care management programs [42][44] Question: Full risk percentage and future potential - The company aims for long-term full risk participation to reach around 50%, with significant revenue implications [70][72] Question: Technology infrastructure and margin management - The company utilizes purpose-built tools and a delegated environment to manage costs effectively [76][78]